[go: up one dir, main page]

PE20091427A1 - Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico - Google Patents

Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico

Info

Publication number
PE20091427A1
PE20091427A1 PE2008001991A PE2008001991A PE20091427A1 PE 20091427 A1 PE20091427 A1 PE 20091427A1 PE 2008001991 A PE2008001991 A PE 2008001991A PE 2008001991 A PE2008001991 A PE 2008001991A PE 20091427 A1 PE20091427 A1 PE 20091427A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
halogen
imidazo
imidazol
Prior art date
Application number
PE2008001991A
Other languages
English (en)
Inventor
Rene M Lemieux
Antonio Jose Del Moral Barbosa
Joerg Martin Bentzien
Steven Richard Brunette
Zhidong Chen
Derek A Cogan
Donghong A Gao
Alexander Heim-Riether
Joshua Courtney Horan
Jennifer A Kowalski
Michael David Lawlor
Weimin Liu
Bryan Mckibben
Craig Andrew Miller
Neil Moss
Matt Aaron Tschantz
Zhaoming Xiong
Hui Yu
Yang Yu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20091427A1 publication Critical patent/PE20091427A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULA I, DONDE R1 ES -CN, -OCF3, HALOGENO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDO CON HALOGENO O ALQUILO C1-3, R2 ES H, CICLOALQUILO C3-6, ALQUILO C1-3 OPCIONALMENTE SUSTITUIDO CON UNO O DOS GRUPOS SELECCIONADOS DE CICLOALQUILO C3-6, -OR9, ENTRE OTROS, R3 ES H O ALQUILO C1-3 O R2 Y R3 FORMAN UN ANILLO HIDROCARBONADO SATURADO DE 3 A 7 ATOMOS DE CARBONO, DONDE UN ATOMO DE CARBONO ESTA OPCIONALMENTE REEMPLAZADO POR -O-, -S-, -S(O)-, ENTRE OTROS, R4 ES ALQUILO C1-5, CICLOALQUILO C3-6, HETEROARILO, OPCIONALMENTE SUSTITUIDO CON DE --NR9R10, -OR9, ENTRE OTROS, R5 ES H, ALQUILO C1-3, -(CH2)2OH Y -(CH2)2OCH3, R6 ES H O HALOGENO, R7 ES HALOGENO O -CF3, R9 ES H, CICLOALQUILO C3-4 O ALQUILO C1-5 EL CUAL ESTA OPCIONALMENTE SUSTITUIDO CON -OH, R10 ES H O -CH3. SON COMPUESTOS PREFERIDOS: ((S)-1-BENCILCARBAMOIL-ETIL)-AMIDA DEL ACIDO (R)-5-(4-CIANO-BENCIL)-7-(3,5-DICLORO-FENIL)-5-METIL-6-OXO-6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-CARBOXILICO, (3R)-3-(4-BROMOBENCIL)-1-(3,5-DICLOROFENIL)-3-METIL-N-{(1S)-1-METIL-2-OXO-2-[(3R)-3(1H-TETRAZOL-5-IL)PIPERIDIN-1-IL]ETIL}-2-OXO-2,3-DIHIDRO-1H-IMIDAZO[1,2-a]IMIDAZOL-5-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS EXHIBEN UN EFECTO INHIBIDOR TRAS LA INTERACCION DE LAS ICAM CON LAS LEUCOINTEGRINAS, SIENDO UTILES PARA EL TRATAMIENTO DE SINDROME DE DIFICULTAD RESPIRATORIA AGUDA, TOXICIDAD POR OXIGENO, INFARTO DE MIOCARDIO, PSORIASIS, ENTRE OTROS
PE2008001991A 2007-11-29 2008-11-27 Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico PE20091427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99096007P 2007-11-29 2007-11-29
US4795708P 2008-04-25 2008-04-25

Publications (1)

Publication Number Publication Date
PE20091427A1 true PE20091427A1 (es) 2009-10-19

Family

ID=40193954

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001991A PE20091427A1 (es) 2007-11-29 2008-11-27 Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico

Country Status (31)

Country Link
US (1) US8552205B2 (es)
EP (1) EP2225238B1 (es)
JP (1) JP5485164B2 (es)
KR (1) KR20100101095A (es)
CN (1) CN101889011B (es)
AR (1) AR069513A1 (es)
AU (1) AU2008329909B2 (es)
BR (1) BRPI0819831A2 (es)
CA (1) CA2705583A1 (es)
CL (1) CL2008003576A1 (es)
CO (1) CO6210701A2 (es)
CY (1) CY1115857T1 (es)
DK (1) DK2225238T3 (es)
EA (1) EA017688B1 (es)
EC (1) ECSP10010196A (es)
ES (1) ES2525237T3 (es)
HR (1) HRP20141171T1 (es)
IL (1) IL205189A (es)
MA (1) MA31905B1 (es)
MX (1) MX2010004995A (es)
MY (1) MY151004A (es)
NZ (1) NZ585640A (es)
PE (1) PE20091427A1 (es)
PL (1) PL2225238T3 (es)
PT (1) PT2225238E (es)
RS (1) RS53602B1 (es)
SI (1) SI2225238T1 (es)
TN (1) TN2010000240A1 (es)
TW (2) TWI475990B (es)
UY (1) UY31493A1 (es)
WO (1) WO2009070485A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5384733B2 (ja) * 2009-06-02 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 6,7−ジヒドロ−5H−イミダゾ[1,2−a]イミダゾール−3−カルボン酸アミドの誘導体
US8575360B2 (en) 2009-06-02 2013-11-05 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amides
PL2491028T3 (pl) 2009-10-21 2014-05-30 Boehringer Ingelheim Int Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
CA2834429C (en) 2011-04-27 2019-07-02 Kyohei Hayashi 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
EP2740730B1 (en) 2011-08-03 2016-11-16 Kyowa Hakko Kirin Co., Ltd. Dibenzooxepin derivative
MX367774B (es) 2011-10-03 2019-09-04 Ogeda S A N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL.
MX375839B (es) 2014-10-14 2025-03-06 Syngenta Participations Ag Proceso para la preparación de 1-(3,5-dicloro-4-fluorofenil)-2,2,2-trifluoroetanona.
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN106631827B (zh) * 2016-12-30 2018-10-23 上海毕得医药科技有限公司 一种(1-环丙基-1-甲基)乙基胺及其盐酸盐的合成方法
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
EP4285723A3 (en) 2019-12-20 2024-03-27 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
CN111848521A (zh) * 2020-08-26 2020-10-30 韶远科技(上海)有限公司 一种2-取代-4-烷氧基咪唑化合物的制备方法
IL318203A (en) * 2022-07-12 2025-03-01 Adama Makhteshim Ltd Process for preparing modified benzamides
WO2025021943A1 (en) 2023-07-26 2025-01-30 Neuralis Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015493A1 (es) * 1968-08-12 1970-04-30 Sumitomo Chemical Co
DK123717B (da) * 1968-11-25 1972-07-24 Sumitomo Chemical Co 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning.
JPS5136332B1 (es) * 1970-12-09 1976-10-07
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
JPS63270667A (ja) 1987-04-30 1988-11-08 Wakamoto Pharmaceut Co Ltd 1−ベンジルイミダゾ−ル誘導体
JPS63270665A (ja) 1987-04-30 1988-11-08 Wakamoto Pharmaceut Co Ltd イミダゾ−ル誘導体
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US4977270A (en) * 1988-12-01 1990-12-11 Ici Americas Inc. Substituted 2,4-dioxodiazolidines and -thiadiazolidines and their use as herbicides
US4911748A (en) * 1988-12-22 1990-03-27 Ici Americas Inc. Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones
JPH04273877A (ja) 1991-02-28 1992-09-30 Sumitomo Pharmaceut Co Ltd 新規なイミダゾール誘導体
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05188631A (ja) 1992-01-10 1993-07-30 Mita Ind Co Ltd 電子写真感光体
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
JP2001525797A (ja) * 1996-10-28 2001-12-11 ザ ユニバーシティ オブ ワシントン ウイルスrnaへのミスコーディングリボヌクレオシドアナログの組込みによるウイルス変異の誘導
US6355664B1 (en) * 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
IL130931A0 (en) 1997-03-03 2001-01-28 Boehringer Ingelheim Pharma Small molecules useful in the treatment of inflammatory disease
PT1007033E (pt) 1997-08-28 2008-07-22 Novartis Ag Antagonistas do antigénio-1 da função de linfócitos
HUP0101587A3 (en) 1998-03-27 2003-03-28 Genentech Inc Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
WO2001007052A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007048A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
ES2306665T3 (es) * 1999-07-21 2008-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Pequeñas moleculas utiles en el tratamiento de la enfermedad inflamatoria.
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007044A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
PT1307455E (pt) 1999-10-20 2005-06-30 Tanabe Seiyaku Co Inibidores de adesao celular mediada por (alfa)l (beta)2
WO2002050080A1 (en) * 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2002058704A1 (en) * 2001-01-26 2002-08-01 Bristol-Myers Squibb Company Imidazolyl derivatives as corticotropin releasing factor inhibitors
US20030232817A1 (en) * 2002-05-29 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful for the treatment of inflammatory disease
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
AU2005269634A1 (en) * 2004-07-27 2006-02-09 Boehringer Ingelheim International, Gmbh Synthesis of 6,7-dihydro-5H-imidazo(1,2-a)imidazole-3-sulfonic acid amides
WO2006107923A1 (en) * 2005-04-05 2006-10-12 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
CA2603214A1 (en) * 2005-04-06 2006-10-12 Steven Richard Brunette Derivatives of[6,7-dihydro-5himidazo[1,2-alpha]imidazole-3-sulfonyl]-azetedine-carboxylic acids, esters and amides and use thereof as anti-inflammatory agents
BRPI0610354A2 (pt) * 2005-05-19 2010-06-15 Boehringer Ingelheim Internac derivados de ácido 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-slfÈnico, bem como composição farmacêutica e uso dos mesmos
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP2080758A3 (de) 2007-11-29 2009-08-26 Bayer CropScience AG Halogen substituierte delta-1-Pyrroline
JP2009149609A (ja) 2007-11-29 2009-07-09 Sumitomo Chemical Co Ltd アミド化合物及びその用途
TWI361690B (en) 2007-11-29 2012-04-11 Actelion Pharmaceuticals Ltd Phosphonic acid derivatives
US8063025B2 (en) 2007-11-29 2011-11-22 Metabasis Therapeutics, Inc. Nucleoside prodrugs and uses thereof
US8575360B2 (en) * 2009-06-02 2013-11-05 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amides
JP5384733B2 (ja) * 2009-06-02 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 6,7−ジヒドロ−5H−イミダゾ[1,2−a]イミダゾール−3−カルボン酸アミドの誘導体

Also Published As

Publication number Publication date
EA201000866A1 (ru) 2010-12-30
ECSP10010196A (es) 2010-07-30
SI2225238T1 (sl) 2014-12-31
UY31493A1 (es) 2009-07-17
CY1115857T1 (el) 2017-01-25
TW200922562A (en) 2009-06-01
CN101889011B (zh) 2014-05-28
AU2008329909A1 (en) 2009-06-04
MY151004A (en) 2014-03-31
JP5485164B2 (ja) 2014-05-07
MX2010004995A (es) 2010-05-20
CO6210701A2 (es) 2010-10-20
EA017688B1 (ru) 2013-02-28
CL2008003576A1 (es) 2010-02-12
RS53602B1 (sr) 2015-02-27
HRP20141171T1 (hr) 2015-01-30
DK2225238T3 (en) 2014-11-24
BRPI0819831A2 (pt) 2019-09-24
TW201417810A (zh) 2014-05-16
HK1145683A1 (en) 2011-04-29
CN101889011A (zh) 2010-11-17
AR069513A1 (es) 2010-01-27
IL205189A0 (en) 2010-12-30
US20110224188A1 (en) 2011-09-15
NZ585640A (en) 2011-03-31
TWI475991B (zh) 2015-03-11
WO2009070485A8 (en) 2014-08-14
US8552205B2 (en) 2013-10-08
AU2008329909A8 (en) 2010-06-03
WO2009070485A1 (en) 2009-06-04
CA2705583A1 (en) 2009-06-04
ES2525237T3 (es) 2014-12-19
MA31905B1 (fr) 2010-12-01
PT2225238E (pt) 2014-12-18
TN2010000240A1 (en) 2011-11-11
PL2225238T3 (pl) 2015-03-31
EP2225238B1 (en) 2014-09-03
EP2225238A1 (en) 2010-09-08
JP2011505359A (ja) 2011-02-24
AU2008329909B2 (en) 2013-10-03
KR20100101095A (ko) 2010-09-16
IL205189A (en) 2014-09-30
TWI475990B (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
PE20091427A1 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20091398A1 (es) Compuestos biciclicos conteniendo nitrogeno activos en condiciones de dolor cronicas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
PE20140161A1 (es) Compuesto biciclico
AR059977A1 (es) Compuesto de ciclohexil piperidinil dihidrobenzimidazol composicion farmaceutica que lo comprende su uso para la preparacion de un medicamento proceso para preparalo y compuesto intermediario para la sintesis del mismo
PE20140934A1 (es) Derivados de pirazol
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
CO6220952A2 (es) Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20061295A1 (es) Derivados de acetileno
CO6260009A2 (es) Derivados de ariloxiacetamida bi-o triciclicos saturados e insaturados y su uso como fungicidas
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed